The subject of study is expected to be treated with the ointment during six weeks.
| RAMAT GAN, Israel, Nov. 29, 2018 /PRNewswire/ -- OWC Pharmaceutical Research Corp. (OTCQB: OWCP), a developer of cannabinoid-based therapies targeting a variety of different medical conditions and disorders, reported today that the safety study of cannabis-based topical ointment, conducted at Shiba Shiba Academic Medical Center, is close to completion as the last healthy volunteer started the treatment three weeks ago. The subject of study is expected to be treated with the ointment during six weeks.
Also, earlier this month OWC Pharmaceutical aroused high level of interest and caught the attention of the industry at MJBizCon. Mr. Mordechai Bignitz, OWC Pharmaceutical CEO said: “MJBizCon was an excellent opportunity for OWC Pharmaceutical to reveal its innovative research and to present the progress and pipeline to investors and potential partners. We look forward to accelerate new opportunities as we strongly believe that our innovative clinical research can unlock the potential of cannabis-based treatment and improve patients’ quality of life.” About OWC Pharmaceutical Research Corp OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., (collectively ‘OWC’ or the ‘Company’) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique and effective delivery systems and dosage forms of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions and led by internationally renowned investigators. Contact: Mordechai Bignitz , Chief Executive Officer - OWC Pharmaceutical research crop,
SOURCE OWC Pharmaceutical Research Corp. |
Company Codes: OTC-PINK:OWCP, OTC-BB:OWCP, OTC-QB:OWCP, OtherOTC:OWCP |
View original content to download multimedia:
